Tenax Therapeutics, Inc.
TENX
$14.61
$0.775.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 249.49% | 258.13% | 194.76% | 125.75% | 35.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.24% | 203.93% | 168.78% | 153.90% | 136.75% |
| Operating Income | -189.24% | -203.93% | -168.78% | -153.90% | -136.75% |
| Income Before Tax | -198.82% | -197.55% | -150.42% | -139.64% | -128.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -198.82% | -197.55% | -150.42% | -139.64% | -128.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.82% | -197.55% | -150.42% | -139.64% | -128.27% |
| EBIT | -189.24% | -203.93% | -168.78% | -153.90% | -136.75% |
| EBITDA | -- | 53.04% | 8.58% | -47.05% | -136.88% |
| EPS Basic | 74.82% | 92.88% | 95.87% | 89.91% | 84.16% |
| Normalized Basic EPS | 74.82% | 92.88% | 95.87% | 89.91% | 84.15% |
| EPS Diluted | 74.82% | 92.88% | 95.87% | 89.91% | 84.16% |
| Normalized Diluted EPS | 74.82% | 92.88% | 95.87% | 89.91% | 84.15% |
| Average Basic Shares Outstanding | 162.97% | 513.68% | 3,413.47% | 4,439.52% | 5,924.11% |
| Average Diluted Shares Outstanding | 162.97% | 513.68% | 3,413.47% | 4,439.52% | 5,924.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |